Intellia Therapeutics (NASDAQ:NTLA) posted its quarterly earnings data on Wednesday. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16), Briefing.com reports. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.31) earnings per share.
Intellia Therapeutics (NTLA) opened at $32.43 on Wednesday. Intellia Therapeutics has a one year low of $11.15 and a one year high of $35.99. The stock has a market cap of $1,200.21, a PE ratio of -21.29 and a beta of 2.42.
In other news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 12.80% of the company’s stock.
NTLA has been the topic of a number of recent research reports. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a research note on Tuesday, December 12th. TheStreet lowered shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, December 14th. BidaskClub upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. ValuEngine lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, JMP Securities initiated coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $33.00.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.